RNA Formulation Videos

  1. Strategies For Scaling Up mRNA Manufacturing 4/11/2022

    The clinical promise of mRNA therapeutics and vaccines is clear, but compared to monoclonal antibodies or viral vectors, their novelty also brings new challenges to the manufacturing process.

  2. RNA Vaccine Development To Phase I 4/14/2022

    Dr. John Lewis, Founder and CEO, Entos Pharmaceuticals, presents RNA Vaccine Development to Phase I.

  3. Groundbreaking Nanoparticle Processing Technology 6/27/2025

    Unlock next-generation nanoparticle and LNP manufacturing. Achieve high throughput, minimal waste, and superior quality with a compact, automated, and contamination-controlled system.

  4. Scale-Up And Production Of Key Lipids Used In mRNA Delivery Systems 2/13/2025

    Discover key strategies for overcoming challenges in the industrial-scale production of ionizable and PEG lipids to optimize mRNA vaccine formulation and address critical manufacturing requirements.

  5. Molecular And Colloidal Ionization Properties Of Lipid Nanoparticle mRNA Vaccines 4/13/2022

    Dr. Michael Buschmann, George Mason University, presents an overview of molecular and colloidal ionization properties of lipid nanoparticle mRNA vaccines.

  6. Durable Liquid Nanoparticle (LNP) Systems 12/6/2024

    Discover the benefits of an LNP system that offers unparalleled durability and sustainability. Eliminate wear parts, plastic waste, and running costs with a system designed for long-term performance and minimal environmental impact.

  7. DNA Vaccine Development In A Global Pandemic: A Personal Account 4/14/2022

    Dr. Gerrit Borchard, University of Geneva, presents a personal account of DNA vaccine development in a global pandemic.

  8. Tissue Adenosine Distribution-Guided Gene Selection 2/17/2025

    Unlike conventional predictive biomarkers, which often focus on isolated molecular markers, this strategy integrates spatial metabolomics and genomics, providing a multidimensional perspective.

  9. mRNA's Future Beyond The COVID Vaccines 11/28/2022

    In this video, Russell Johnson, VP Formulation Research for RVAC Medicines, and Aalok Shah, Director of Formulation & Drug Delivery, Strand Therapeutics, unpack which learnings can be adapted from ASO-LNPs to mRNA/LNPs and from mRNA vaccines to mRNA therapeutics. They also touch upon which learnings cannot be neatly carried over from these previous success stories.

  10. Deciphering mRNA Immunogenicity: Early Assessment Of Human Immune Response 6/4/2024

    Review strategies to assess the potential for human immune response following the administration of an mRNA therapeutic, the associated LNP, and the protein encoded for by the mRNA.